Clinical relevance of amyloid deposits in the ligamentum flavum and muscle M47
Conditions
Interventions
Group 1: Patients with several degenerative spinal diseases, who undergo surgery for spondylodesis:
immunhistochemical analysis for amyloid-deposits in ligamentum flavum and paravertebrale muscule tis
Sponsors
Universitätsklinikum BG Bergmannsheil GmbH Neurochirurgie und Traumatologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Arm1: Patients, where a dorsal surgery (decompression, spondylodesis) of the thoracolumbar spine is indicated based on a degenerative spine disease For the control-group: Patients that do not suffer from a degenerative spine disease but have to undergo surgery based on a "non degenerative" indikation, like spinal trauma or spinal tumour
Exclusion criteria
Exclusion criteria: - patients that are unable to be informed - pregnancy - patients with a diagnosed autoimmune- or muscle disease - patients with rheuma or a tumour (the control group can be included in cases of a spinal tumour) - patients that are undertaking an oral or intravenal cortisone, cytostatical or immunesuppressive therapy - patients that are unable to give written consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aim of this study is the clinical significance of amyloid deposits in the ligamentum flavum and muscle (paraspinal musculature) in degenerative changes of the spinal column (e. g. muscle fatigue or hypertrophy of the ligamentum flavum), on the progression of lumbar spinal degeneration before and after lumbar operations of the thoracolumbar vertebral column. In this research project, biopsies of the ligamentum flavum and the paravertebral musculature are collected prospectively during the surgical procedure at the access area. The biopsies taken are to be examined for sarcolematous and interstitial amyloid deposits as well as for histological features indicating muscle degeneration. To this end, hematoxyline-eosin staining and immunohistochemical detection of transthyretin-amyloid will be performed. Transthyretin is also to be measured in the serum of these patients. In addition, the serum level of the inflammation marker IL-1ß is to be determined. The experimental findings will then be correlated with clinical data during the course of the study (sonography - pre-surgical, after 6 weeks, 6 months and 1 year in each case; MRI - pre-surgical and after 6 months - and e. g. VAS - after 6 months and 1 year). The follow-ups extend for 1 year after surgery. | — |
Countries
Germany
Contacts
Public ContactBogdan Pintea (Deputy Prinicipal Investigator)
Universitätsklinikum BG Bergmannsheil GmbH
Outcome results
None listed